BG Medicine to Highlight Role of Galectin-3 Testing in Reducing Unplanned Hospital Readmissions at the 2012 American Heart

BG Medicine to Highlight Role of Galectin-3 Testing in Reducing Unplanned
Hospital Readmissions at the 2012 American Heart Association (AHA) Scientific
Sessions

WALTHAM, Mass. and LOS ANGELES, Nov. 5, 2012 (GLOBE NEWSWIRE) -- BG Medicine,
Inc. (Nasdaq:BGMD), a company focused on the development and commercialization
of novel cardiovascular diagnostics, today announced that it will be launching
a major initiative to help hospitals reduce the number of unplanned
readmissions for heart failure patients, beginning at the American Heart
Association (AHA) Scientific Sessions 2012 taking place Nov. 3-7, 2012 in Los
Angeles, California. Representatives at the BG Medicine booth (#1737) will be
on hand to highlight the role that galectin-3 blood testing can play in
helping hospitals address the urgent need to reduce readmission rates.

Since taking effect on October 1, 2012, new rules from the federal Centers for
Medicare & Medicaid Services (CMS) have made reducing unplanned hospital
readmissions a critical priority. Hospitals that exceed the Medicare
thresholds will be assessed financial penalties that are expected to reach an
aggregate of nearly $300 million this year alone, and nearly $1 billion by
2015, if improvements are not made.

Even with optimal care, today nearly a quarter of all Medicare heart failure
patients are readmitted to the hospital within 30 days^1, making heart failure
a major driver of hospital readmission rates, far ahead of myocardial
infarction and pneumonia. Because heart failure patients with elevated
galectin-3 are two-to-three times more likely to be readmitted to the hospital
within 30 days of discharge, identifying these high-risk patients through
galectin-3 testing is a potentially valuable and cost-effective tool in a
hospital's strategy to reduce unplanned 30-day readmissions. Identifying those
at greater risk with galectin-3 testing enables hospitals to better direct
their intervention strategies and resources to those who need them most,
potentially providing a way to improve outcomes while also controlling costs
and avoiding penalties.

"Patient stratification tools that help predict risk of near-term readmission
would allow the clinician to better direct more resource-intensive heart
failure disease management efforts to patients at higher risk," said Rudolf A.
de Boer, MD, PhD, Associate Professor of Cardiology at the University Medical
Center Groningen in the Netherlands. "Such tools would be usable upon
discharge, with a simple interpretation such as a single threshold value.
Galectin-3 is such a tool and should be considered for heart failure
readmissions programs. Baseline galectin-3 is a powerful predictor of
unplanned hospital readmissions and, importantly, adds significantly to other
risk factors such as age, reduced renal function, diminished left ventricular
pumping capacity and BNP levels."

The BG Medicine booth at AHA will include an interactive demonstration that
will enable health care professionals and hospital administrators to determine
the financial impact of utilizing galectin-3 testing at their hospitals as
part of a comprehensive readmissions reduction strategy. The BG Medicine
Galectin-3 Readmissions Calculator being introduced at AHA will enable users
to determine the potential financial impact of galectin-3 testing instantly,
factoring in the costs of testing and of implementing a targeted intervention
initiative, as well as the reduction in costs associated with lower
readmissions and avoidance of Medicare penalties.

"Galectin-3 testing is a powerful tool for those seeking to make their
intervention strategies on patients with clinical variations more targeted,
efficient and effective," said Eric Bouvier, President and CEO of BG Medicine.
"We look forward to expanding our efforts to help health professionals address
this urgent issue."

The BGM Galectin-3^® Test is cleared by the FDA as an aid in assessing the
prognosis of patients with chronic heart failure.

About Galectin-3 and Heart Failure

Galectin-3 is a unique carbohydrate-binding lectin, or protein, that binds to
carbohydrates called beta-galactosides. Galectin-3 has been implicated in a
variety of biological processes important in the development and progression
of heart failure, and is believed to be a primary mediator of progressive
cardiac fibrosis (abnormal thickening and stiffening of the heart muscle) and
adverse remodeling (changes in the structure of the heart). Higher levels of
galectin-3 are associated with a more aggressive form of heart failure and 30%
or more of mild to moderate heart failure patients will have elevated levels
of galectin-3. Heart failure affects an estimated 5.8 million Americans, with
approximately 670,000 new cases occurring each year.The direct and indirect
cost of heart failure in the United States for 2010 is estimated to be $39.2
billion.

About BG Medicine, Inc.

BG Medicine, Inc. (Nasdaq:BGMD) is a life sciences company focused on the
discovery, development and commercialization of novel cardiovascular
diagnostics to address significant unmet medical needs, improve patient
outcomes and contain healthcare costs. The Company's first commercialized
product, the BGM Galectin-3^® Test for use in patients with heart failure, is
available in the United States and Europe.BG Medicine is also developing the
CardioSCORE ^ TM Test, a blood test designed to identify individuals at high
risk for near-term major cardiovascular events, such as heart attack and
stroke.For additional information about BG Medicine, heart failure and
galectin-3 testing, please visit www.bg-medicine.com and www.galectin-3.com.

The BG Medicine Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=10352

Special Note Regarding Forward-looking Statements

Certain statements made in this news release contain forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities and Exchange Act of 1934, as
amended, that are intended to be covered by the "safe harbor" created by those
sections. Forward-looking statements, which are based on certain assumptions
and describe our future plans, strategies and expectations, can generally be
identified by the use of forward-looking terms such as "believe," "expect,"
"may," "will," "should," "could," "seek," "intend," "plan," "estimate,"
"anticipate" or other comparable terms.Forward-looking statements in this
news release address our understanding that heart failure patients with
elevated galectin-3 are two-to-three times more likely to be readmitted to the
hospital within 30 days of discharge than other heart failure patients; our
belief that identifying these high-risk patients through galectin-3 testing is
a potentially valuable and cost-effective tool in reducing unplanned
readmissions; our belief that identifying patients at greater risk with
galectin-3 testing enables hospitals to more efficiently and cost-effectively
direct intervention strategies and resources; our belief that increased usage
of galectin-3 testing by the healthcare system may improve health outcomes and
reduce healthcare costs.Forward-looking statements are based on management's
current expectations and involve inherent risks and uncertainties which could
cause actual results to differ materially from those in the forward-looking
statements, as a result of various factors including those risks and
uncertainties described in the Risk Factors and in Management's Discussion and
Analysis of Financial Condition and Results of Operations sections of our
recent filings with the Securities and Exchange Commission, including our most
recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.We urge
you to consider those risks and uncertainties in evaluating our
forward-looking statements.We caution readers not to place undue reliance
upon any such forward-looking statements, which speak only as of the date
made.Except as otherwise required by the federal securities laws, we disclaim
any obligation or undertaking to publicly release any updates or revisions to
any forward-looking statement contained herein (or elsewhere) to reflect any
change in our expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is based.

^1 Data.Medicare.Gov Hospital Outcomes of Care Measures – National Average.
https://data.medicare.gov/d/i2h8-79qx. Accessed September 28, 2012.

CONTACT: Charles Abdalian
         EVP & Chief Financial Officer
         (781) 890-1199

BG Medicine Inc. logo
 
Press spacebar to pause and continue. Press esc to stop.